Regulatory role of GSK-3 β on NF-B, nitric oxide, and TNF-α in group A streptococcal infection

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Chang, Yu Tzu ^a   Chen, Chia Ling ^a   Lin, Chiou Feng ^a   Lu, Shiou Ling ^a   Cheng, Miao Huei ^a   Kuo, Chih Feng ^b   Lin, Yee Shin ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

ANIMAL CELL; ARTICLE; CYTOKINE PRODUCTION; GROUP A STREPTOCOCCAL INFECTION; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SURVIVAL RATE; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CELL SURVIVAL; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; STREPTOCOCCUS INFECTION; WESTERN BLOTTING;

MURINAE; STREPTOCOCCUS SP. 'GROUP A';

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MICE; MICE, INBRED BALB C; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; STREPTOCOCCAL INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875432622     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/720689     Document Type: Article

References (58)

1. Cunningham M. W., Pathogenesis of group a streptococcal infections. Clinical Microbiology Reviews 2000 13 3 470 511 2-s2.0-0033939735 10.1128/CMR.13.3.470-511.2000 (Pubitemid 30452618)
2. Musser J. M., Shelburne S. A., A decade of molecular pathogenomic analysis of group A Streptococcus. Journal of Clinical Investigation 2009 119 9 2455 2463 2-s2.0-70349223864 10.1172/JCI38095
3. Cole J. N., Barnett T. C., Nizet V., Walker M. J., Molecular insight into invasive group A streptococcal disease. Nature Reviews Microbiology 2011 9 10 724 736 10.1038/nrmicro2648
4. Dale J. B., Washburn R. G., Marques M. B., Wessels M. R., Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infection and Immunity 1996 64 5 1495 1501 2-s2.0-0029922220 (Pubitemid 26129807)
5. Berggård K., Johnsson E., Morfeldt E., Persson J., Stålhammar-Carlemalm M., Lindahl G., Binding of human C4BP to the hypervariable region of M protein: a molecular mechanism of phagocytosis resistance in Streptococcus pyogenes. Molecular Microbiology 2001 42 2 539 551 2-s2.0-0034768706 10.1046/j.1365-2958.2001.02664.x (Pubitemid 32990140)
6. Ji Y., McLandsborough L., Kondagunta A., Cleary P. P., C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infection and Immunity 1996 64 2 503 510 2-s2.0-9044220226 (Pubitemid 26032821)
7. Carapetis J. R., Steer A. C., Mulholland E. K., Weber M., The global burden of group A streptococcal diseases. The Lancet Infectious Diseases 2005 5 11 685 694 2-s2.0-27144468026 10.1016/S1473-3099(05)70267-X (Pubitemid 41505357)
8. Stevens D. L., Invasive group A Streptococcus infections. Clinical Infectious Diseases 1992 14 1 2 11 2-s2.0-0026580187
9. Norrby-Teglund A., Chatellier S., Low D. E., McGeer A., Green K., Kotb M., Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. European Journal of Immunology 2000 30 11 3247 3255 10.1002/1521-4141(200011)30:11<3247::AID- IMMU3247>3.0.CO;2-D
10. Norrby-Teglund A., Pauksens K., Norgren M., Holm S. E., Correlation between serum TNF α and IL6 levels and severity of group A streptococcal infections. Scandinavian Journal of Infectious Diseases 1995 27 2 125 130 2-s2.0-0028989074
11. Kapur V., Majesky M. W., Li L. L., Black R. A., Musser J. M., Cleavage of interleukin 1 β (IL-1 β) precursor to produce active IL-1 β by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proceedings of the National Academy of Sciences of the United States of America 1993 90 16 7676 7680 2-s2.0-0027290733 (Pubitemid 23250013)
12. Muller-Alouf H., Alouf J. E., Gerlach D., Ozegowski J. H., Fitting C., Cavaillon J. M., Comparative study of cytokine release by human peripheral blood mononuclear cells stimulated with Streptococcus pyogenes superantigenic erythrogenic toxins, heat-killed streptococci, and lipopolysaccharide. Infection and Immunity 1994 62 11 4915 4921 2-s2.0-0027940585 (Pubitemid 24332796)
13. Hackett S. P., Stevens D. L., Superantigens associated with staphylococcal and streptococcal toxic shock syndrome are potent inducers of tumor necrosis factor- β synthesis. Journal of Infectious Diseases 1993 168 1 232 235 2-s2.0-0027215479 (Pubitemid 23178757)
14. Frame S., Cohen P., GSK3 takes centre stage more than 20 years after its discovery. Biochemical Journal 2001 359 1 1 16 2-s2.0-0035477020 10.1042/0264-6021:3590001 (Pubitemid 32939202)
15. Cohen P., Frame S., The renaissance of GSK3. Nature Reviews Molecular Cell Biology 2001 2 10 769 776 2-s2.0-0035488986 10.1038/35096075 (Pubitemid 33679839)
16. Dugo L., Collin M., Thiemermann C., Glycogen synthase kinase 3 β as a target for the therapy of shock and inflammation. Shock 2007 27 2 113 123 2-s2.0-33846225968 10.1097/01.shk.0000238059.23837.68 (Pubitemid 46105826)
17. Jope R. S., Yuskaitis C. J., Beurel E., Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochemical Research 2007 32 4-5 577 595 2-s2.0-33947597084 10.1007/s11064-006-9128-5 (Pubitemid 46481289)
18. Hoeflich K. P., Luo J., Rubie E. A., Tsao M. S., Jin O., Woodgett J. R., Requirement for glycogen synthase kinase-3 β in cell survival and NF- B activation. Nature 2000 406 6791 86 90 2-s2.0-0034612636 10.1038/35017574 (Pubitemid 30460216)
19. Saijo K., Winner B., Carson C. T., Collier J. G., Boyer L., Rosenfeld M. G., Gage F. H., Glass C. K., A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009 137 1 47 59 2-s2.0-63049083734 10.1016/j.cell.2009.01.038
20. Martin M., Rehani K., Jope R. S., Michalek S. M., Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nature Immunology 2005 6 8 777 784 2-s2.0-23944486750 10.1038/ni1221 (Pubitemid 43090463)
21. Beurel E., Jope R. S., Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. Journal of Neuroinflammation 2009 6 article 9 2-s2.0-63549151154 10.1186/1742-2094-6-9
22. Chan M. M. P., Cheung B. K. W., Li J. C. B., Chan L. L. Y., Lau A. S. Y., A role for glycogen synthase kinase-3 in antagonizing mycobacterial immune evasion by negatively regulating IL-10 induction. Journal of Leukocyte Biology 2009 86 2 283 291 2-s2.0-69449095622 10.1189/jlb.0708442
23. Dugo L., Collin M., Allen D. A., Patel N. S. A., Bauer I., Mervaala E. M. A., Louhelainen M., Foster S. J., Yaqoob M. M., Thiemermann C., GSK-3 β inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Critical Care Medicine 2005 33 9 1903 1912 2-s2.0-24944567775 10.1097/01.CCM.0000178350.21839.44 (Pubitemid 41306508)
24. Woodgett J. R., Ohashi P. S., GSK3: an in-toll-erant protein kinase? Nature Immunology 2005 6 8 751 752 2-s2.0-23944499155 10.1038/ni0805-751 (Pubitemid 43090457)
25. Cremer T. J., Shah P., Cormet-Boyaka E., Valvano M. A., Butchar J. P., Tridandapani S., Akt-mediated proinflammatory response of mononuclear phagocytes infected with Burkholderia cenocepacia occurs by a novel GSK3 β -dependent, I B kinase-independent mechanism. Journal of Immunology 2011 187 2 635 643 2-s2.0-79960516624 10.4049/jimmunol.1003034
26. Zhang P., Katz J., Michalek S. M., Glycogen synthase kinase-3 β (GSK3 β) inhibition suppresses the inflammatory response to Francisella infection and protects against tularemia in mice. Molecular Immunology 2009 46 4 677 687 2-s2.0-58249117791 10.1016/j.molimm.2008.08.281
27. Burnham C. A. D., Shokoples S. E., Tyrrell G. J., Invasion of HeLa cells by group B streptococcus requires the phosphoinositide-3-kinase signalling pathway and modulates phosphorylation of host-cell Akt and glycogen synthase kinase-3. Microbiology 2007 153 12 4240 4252 2-s2.0-37449032424 10.1099/mic.0.2007/008417-0
28. Oviedo-Boyso J., Cortes-Vieyra R., Huante-Mendoza A., The phosphoinositide-3-kinase-Akt signaling pathway is important for Staphylococcus aureus internalization by endothelial cells.,Infection and Immunity 2011 79 11 4569 4577 10.1128/IAI.05303-11
29. Goldmann O., Rohde M., Chhatwal G. S., Medina E., Role of macrophages in host resistance to group A streptococci. Infection and Immunity 2004 72 5 2956 2963 2-s2.0-2142768811 10.1128/IAI.72.5.2956-2963.2004 (Pubitemid 38542426)
30. Kuo C. F., Wu J. J., Lin K. Y., Tsai P. J., Lee S. C., Jin Y. T., Lei H. Y., Lin Y. S., Role of streptococcal pyrogenic exotoxin B in the mouse model of group A streptococcal infection. Infection and Immunity 1998 66 8 3931 3935 2-s2.0-0031870998
31. Kuo C. F., Luo Y. H., Lin H. Y., Huang K. J., Wu J. J., Lei H. Y., Lin M. T., Chuang W. J., Liu C. C., Jin Y. T., Lin Y. S., Histopathologic changes in kidney and liver correlate with streptococcal pyrogenic exotoxin B production in the mouse model of group A streptococcal infection. Microbial Pathogenesis 2004 36 5 273 285 2-s2.0-12144291071 10.1016/j.micpath.2004.01.003 (Pubitemid 38388257)
32. Ghosh S., May M. J., Kopp E. B., NF- B and rel proteins: evolutionarily conserved mediators of immune responses. Annual Review of Immunology 1998 16 225 260 2-s2.0-0031897632 10.1146/annurev.immunol.16.1.225 (Pubitemid 28183365)
33. Bonizzi G., Karin M., The two NF- B activation pathways and their role in innate and adaptive immunity. Trends in Immunology 2004 25 6 280 288 2-s2.0-2342464085 10.1016/j.it.2004.03.008 (Pubitemid 38610351)
34. Tsai P. J., Chen Y. H., Hsueh C. H., Hsieh H. C., Liu Y. H., Wu J. J., Tsou C. C., Streptococcus pyogenes induces epithelial inflammatory responses through NF- B/MAPK signaling pathways. Microbes and Infection 2006 8 6 1440 1449 2-s2.0-33745133755 10.1016/j.micinf.2006.01.002 (Pubitemid 43903312)
35. Takada Y., Fang X., Jamaluddin M. S., Boyd D. D., Aggarwal B. B., Genetic deletion of glycogen synthase kinase-3 β abrogates activation of I B α kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. The Journal of Biological Chemistry 2004 279 38 39541 39554 2-s2.0-4544341116 10.1074/jbc.M403449200 (Pubitemid 39258221)
36. Dugo L., Abdelrahman M., Murch O., Mazzon E., Cuzzocrea S., Thiemermann C., Glycogen synthase kinase-3 β inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation. Shock 2006 25 5 485 491 2-s2.0-33646815707 10.1097/01.shk.0000209545.29671.31
37. Hertzén E., Johansson L., Wallin R., Schmidt H., Kroll M., Rehn A. P., Kotb M., Mörgelin M., Norrby-Teglund A., M1 protein-dependent intracellular trafficking promotes persistence and replication of Streptococcus pyogeness in macrophages. Journal of Innate Immunity 2010 2 6 534 545 2-s2.0-77958177658 10.1159/000317635
38. Akira S., Uematsu S., Takeuchi O., Pathogen recognition and innate immunity. Cell 2006 124 4 783 801 2-s2.0-32944464648 10.1016/j.cell.2006.02.015 (Pubitemid 43261452)
39. Cheng Y. L., Wang C. Y., Huang W. C., Tsai C. C., Chen C. L., Shen C. F., Chi A. Y., Lin C. F., Staphylococcus aureus induces microglial inflammation via a glycogen synthase kinase 3 β -regulated pathway. Infection and Immunity 2009 77 9 4002 4008 2-s2.0-69049102099 10.1128/IAI.00176-09
40. Loof T. G., Goldmann O., Medina E., Immune recognition of Streptococcus pyogenes by dendritic cells. Infection and Immunity 2008 76 6 2785 2792 2-s2.0-46249092324 10.1128/IAI.01680-07
41. Gratz N., Siller M., Schaljo B., Pirzada Z. A., Gattermeier I., Vojtek I., Kirschning C. J., Wagner H., Akira S., Charpentier E., Kovarik P., Group A streptococcus activates type I interferon production and MyD88-dependent signaling without involvement of TLR2, TLR4, and TLR9. The Journal of Biological Chemistry 2008 283 29 19879 19887 2-s2.0-50649115777 10.1074/jbc.M802848200
42. Li Q., Verma I. M., NF- B regulation in the immune system. Nature Reviews Immunology 2002 2 10 725 734
43. Baeuerle P. A., Baichwal V. R., NF- B as a frequent target for immunosuppressive and anti-inflammatory molecules. Advances in Immunology 1997 65 111 137 2-s2.0-0030747128 (Pubitemid 27323247)
44. Tak P. P., Firestein G. S., NF- B: a key role in inflammatory diseases. Journal of Clinical Investigation 2001 107 1 7 11 2-s2.0-0034746919
45. Obligado S. H., Ibraghimov-Beskrovnaya O., Zuk A., Meijer L., Nelson P. J., CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney International 2008 73 6 684 690 2-s2.0-40049091449 10.1038/sj.ki.5002731 (Pubitemid 351323251)
46. Cortes-Vieyra R., Bravo-Patino A., Valdez-Alarcon J. J., Juarez M. C., Finlay B. B., Baizabal-Aguirre V. M., Role of glycogen synthase kinase-3 beta in the inflammatory response caused by bacterial pathogens. Journal of Inflammation 2012 9 1 23 31 10.1186/1476-9255-9-23
47. Huang W. C., Lin Y. S., Wang C. Y., Tsai C. C., Tseng H. C., Chen C. L., Lu P. J., Chen P. S., Qian L., Hong J. S., Lin C. F., Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide- induced iNOS/NO biosynthesis and RANTES production in microglial cells. Immunology 2009 128 1 e275 e286 2-s2.0-68249159584 10.1111/j.1365-2567.2008. 02959.x
48. Chen L., Ren F., Zhang H., Inhibition of glycogen synthase kinase 3 β ameliorates D-GalN/LPS-induced liver injury by reducing endoplasmic reticulum stress-triggered apoptosis. PLoS ONE 2012 7 9 e45202 10.1371/journal.pone.0045202
49. Tsai C. C., Kai J. I., Huang W. C., Wang C. Y., Wang Y., Chen C. L., Fang Y. T., Lin Y. S., Anderson R., Chen S. H., Tsao C. W., Lin C. F., Glycogen synthase kinase-3 β facilitates IFN- γ -induced STAT1 activation by regulating Src homology-2 domain-containing phosphatase 2. Journal of Immunology 2009 183 2 856 864 2-s2.0-70249114863 10.4049/jimmunol.0804033
50. Parameswaran N., Patial S., Tumor necrosis factor- α signaling in macrophages. Critical Reviews in Eukaryotic Gene Expression 2010 20 2 87 103 2-s2.0-79651471957
51. Takada Y., Aggarwal B. B., Genetic deletion of the tumor necrosis factor receptor p60 or p80 sensitizes macrophages to lipopolysaccharide-induced nuclear factor- B, mitogen-activated protein kinases, and apoptosis. The Journal of Biological Chemistry 2003 278 26 23390 23397 2-s2.0-0038607575 10.1074/jbc.M213237200 (Pubitemid 36830155)
52. Takada Y., Sung B., Sethi G., Chaturvedi M. M., Aggarwal B. B., Evidence that genetic deletion of the TNF receptor p60 or p80 inhibits Fas mediated apoptosis in macrophages. Biochemical Pharmacology 2007 74 7 1057 1064 2-s2.0-34548036305 10.1016/j.bcp.2007.07.005 (Pubitemid 47284012)
53. Kobayashi Y., The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation. Journal of Leukocyte Biology 2010 88 6 1157 1162 2-s2.0-78649736380 10.1189/jlb.0310149
54. Russell J. A., Management of sepsis. The New England Journal of Medicine 2006 355 16 1699 1713 10.1056/NEJMra043632 (Pubitemid 44583960)
55. Abraham E., Laterre P. F., Garbino J., Pingleton S., Butler T., Dugernier T., Margolis B., Kudsk K., Zimmerli W., Anderson P., Reynaert M., Lew D., Lesslauer W., Passe S., Cooper P., Burdeska A., Modi M., Leighton A., Salgo M., van der Auwera P., Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Critical Care Medicine 2001 29 3 503 510 2-s2.0-0035100346 (Pubitemid 32225290)
56. Abraham E., Wunderink R., Silverman H., Perl T. M., Nasraway S., Levy H., Bone R., Wenzel R. P., Balk R., Allred R., Pennington J. E., Wherry J. C., Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. The Journal of the American Medical Association 1995 273 12 934 941 2-s2.0-0028957549 10.1001/jama.273.12.934
57. Fisher C. J. Jr., Dhainaut J. F. A., Opal S. M., Pribble J. P., Balk R. A., Slotman G. J., Iberti T. J., Rackow E. C., Shapiro M. J., Greenman R. L., Reines H. D., Shelly M. P., Thompson B. W., LaBrecque J. F., Catalano M. A., Knaus W. A., Sadoff J. C., Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. The Journal of the American Medical Association 1994 271 23 1836 1843 2-s2.0-0028239555 10.1001/jama.271.23.1836 (Pubitemid 24169697)
58. Kuo C. F., Wu J. J., Tsai P. J., Kao F. J., Lei H. Y., Lin M. T., Lin Y. S., Streptococcal pyrogenic exotoxin B induces apoptosis and reduces phagocytic activity in U937 cells. Infection and Immunity 1999 67 1 126 130 2-s2.0-0032894568 (Pubitemid 29021639)